Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1135-1139. doi: 10.19723/j.issn.1671-167X.2020.06.025

Previous Articles     Next Articles

Rheumatoid arthritis combined with pigmented villonodular synovitis: A case report and literature review

Jia-jing PENG,Tian LIU()   

  1. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2020-07-25 Online:2020-12-18 Published:2020-12-13
  • Contact: Tian LIU E-mail:mikle317@163.com

RICH HTML

  

Abstract:

We reported a case of rheumatoid arthritis (RA) combined with pigmented villonodular synovitis (PVNS) from Peking University People’s Hospital. The clinical data were introduced and the related literature was reviewed. The clinical features, treatment and prognosis of the disease were summarized to improve clinicians’ understanding of this rare disease and avoid misdiagnosis and delayed diagnosis. A 45-year-old female, with 15 years of RA history and unregular treatment, was admitted to the hospital with the complaint of aggravating pain and swelling in the right knee for 3 months. The puncture of the right knee was performed and there was a large amount of bloody synovial fluid that could not be explained by her RA history. Moreover, the magnetic resonance imaging (MRI) of the right knee revealed hemosiderin deposition with low-intensity signals on both T1-weighted and T2-weighted images which suggested PVNS to us. Then, the patient underwent knee arthroscopy and biopsy to assist in diagnosis. The arthroscopic appearance and pathology were consistent with PVNS and the hyperplastic synovium was removed during arthroscopy. After the operation, she did active functional exercises and took disease-modifying antirheumatic drugs to control RA. She recovered well and remained asymptomatic after half a year of follow-up. Also, there was no recurrence of the right knee. As we all know, RA is a systemic autoimmune disease characterized by chronic synovitis and joint damage. And PVNS is characterized by synovial proliferation and infiltrative process. Both of them are synovial involvement and the clinical manifestations are quite similar. PVNS has occasionally been reported in association with RA. So it is difficult to make a clear diagnosis of RA combined with PVNS. Literature was searched with RA+PVNS in the WanFang Medical Network Database and China National Knowledge Infrastructure and there were no related Chinese cases. Then we searched literature from PubMed with RA+PVNS. The cases were still rare and eventually 2 related articles were yielded including 2 similar patients. It is necessary to fully understand the disease development, complicated MRI appearance and various pathological morpho-logy. They can contribute to making a correct diagnosis which is effective to guide the proper treatment.

Key words: Pigmented villonodular synovitis, Rheumatoid arthritis, Synovial fluid, Hemarthrosis

CLC Number: 

  • R593.22

Figure 1

Arthroscopic appearance Arthroscope showed synovial hypertrophy was diffuse, the multiple definite nodules were seen."

Figure 2

Postoperative pathology (HE ×100) Histological image showed villous formation with giant cells stained hemosiderin, proliferation of small blood vessels and interstitial fibrous tissue with hyaline change."

Table 1

Clinical data of 3 rheumatoid arthritis patients combined with pigmented villonodular synovitis"

Study Gender Age/years Duration/years Affected
joints of PVNS
Affected joints of RA WBC/
(×109/L)
HB/
(g/L)
PLT/
(×109/L)
This study Female 45 15 Right knee Wrist, MCP, PIP, knee 4 129 188
Hirose et al[3] Female 38 5.3 Right knee Wrist, MCP, ankle, knee 3.5 121 300
Zhao et al[4] Male 56 3 Right knee Wrist, MCP, PIP, knee - - -
Study ESR/(mm/h) CRP/(mg/L) RF/(IU/mL) Anti-CCP/(U/mL) MRI Synovial fluid Arthroscopy Radiation
therapy
This study 11 0.39 <20 137.9 Soft-tissue mass
with low intensity signals
on T1-weighted and
T2-weighted images(all
these three patients had
such MRI manifestations)
Bloody Once No
Hirose et al[3] 82 2.7 151 - Bloody Twice Yes
Zhao et al[4] 34 44.6 238 >200 Bloody Once No
[1] Croia C, Bursi R, Sutera D, et al. One year in review 2019: pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2019,37(3):347-357.
pmid: 31111823
[2] Ottaviani S, Ayral X, Dougados M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature[J]. Semin Arthritis Rheum, 2011,40(6):539-546.
doi: 10.1016/j.semarthrit.2010.07.005 pmid: 20884045
[3] Hirose I, Mori Y, Fujimoto A. Case report: rheumatoid arthritis occurring during observation after surgery for localized pigmented villonodular synovitis[J]. Mod Rheumatol, 2003,13(3):281-284.
pmid: 24387219
[4] Zhao X, Ji W, Qian X, et al. Pigmented villonodular synovitis developing in a patient with rheumatoid arthritis[J]. J Clin Rheumatol, 2014,20(5):283-286.
doi: 10.1097/RHU.0000000000000119 pmid: 25036563
[5] Dougados M. Synovial fluid cell analysis[J]. Baillieres Clin Rheumatol, 1996,10(3):519-534.
pmid: 8876957
[6] Myers BW, Masi AT. Pigmented villonodular synovitis and tenosynovitis: A clinical epidemiologic study of 166 cases and literature review[J]. Medicine (Baltimore), 1980,59(3):223-238.
[7] Mastboom M, Verspoor F, Verschoor A, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors[J]. Acta orthopaedica, 2017,88(6):688-694.
doi: 10.1080/17453674.2017.1361126 pmid: 28787222
[8] Fiocco U, Sfriso P, Lunardi F, et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis[J]. Autoimmun Rev, 2010,9(11):780-784.
doi: 10.1016/j.autrev.2010.07.001 pmid: 20620241
[9] Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)[J]. Orthop Traumatol Surg Res, 2017,103(1S):S91-S97.
doi: 10.1016/j.otsr.2016.11.002 pmid: 28057477
[10] Staals E, Ferrari S, Donati D, et al. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives[J]. Eur J Cancer, 2016,63:34-40.
doi: 10.1016/j.ejca.2016.04.022 pmid: 27267143
[11] Cupp J, Miller M, Montgomery K, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides[J]. Am J Surg Pathol, 2007,31(6):970-976.
doi: 10.1097/PAS.0b013e31802b86f8 pmid: 17527089
[12] Oliviero F, Galozzi P, Ramonda R, et al. Unusual findings in synovial fluid analysis: A review[J]. Ann Clin Lab Sci, 2017,47(3):253-259.
pmid: 28667024
[13] 列锐锋. 膝关节色素沉着绒毛结节性滑膜炎MRI表现[J]. 罕少疾病杂志, 2020,27(2):67-69.
[14] Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis[J]. Knee, 2017,24(4):851-855.
doi: 10.1016/j.knee.2017.04.019 pmid: 28552192
[15] Barile A, Sabatini M, Iannessi F, et al. Pigmented villonodular synovitis (PVNS) of the knee joint: magnetic resonance imaging (MRI) using standard and dynamic paramagnetic contrast media. Report of 52 cases surgically and histologically controlled[J]. Radiol Med, 2004,107(4):356-366.
pmid: 15103287
[16] 巫娟, 徐钢, 傅静. 膝关节色素沉着绒毛结节性滑膜炎的临床病理分析[J]. 四川医学, 2017,38(9):1010-1013.
[17] Bernthal N, Ishmael C, Burke Z. Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon’s perspective[J]. Curr Oncol Rep, 2020,22(6):63.
pmid: 32494892
[18] Palmerini E, Staals E, Maki R, et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors[J]. Eur J Cancer, 2015,51(2):210-217.
doi: 10.1016/j.ejca.2014.11.001 pmid: 25465190
[19] Tap W, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial[J]. Lancet, 2019,394(10197):478-487.
doi: 10.1016/S0140-6736(19)30764-0 pmid: 31229240
[20] Monestime S, Lazaridis D. Pexidartinib (TURALIO?): The first FDA-indicated systemic treatment for tenosynovial giant cell tumor[J]. Drugs R D, 2020,20(3):189-195.
doi: 10.1007/s40268-020-00314-3 pmid: 32617868
[21] Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2018,19(5):639-648.
doi: 10.1016/S1470-2045(18)30143-8 pmid: 29571946
[1] Dongwu LIU, Jie CHEN, Mingli GAO, Jing YU. Rheumatoid arthritis with Castleman-like histopathology in lymph nodes: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 928-931.
[2] Huina HUANG,Jing ZHAO,Xiangge ZHAO,Ziran BAI,Xia LI,Guan WANG. Regulatory effect of lactate on peripheral blood CD4+ T cell subsets in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 519-525.
[3] Xiaofei TANG,Yonghong LI,Qiuling DING,Zhuo SUN,Yang ZHANG,Yumei WANG,Meiyi TIAN,Jian LIU. Incidence and risk factors of deep vein thrombosis in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 279-283.
[4] Xue ZOU,Xiao-juan BAI,Li-qing ZHANG. Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1013-1021.
[5] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
[6] Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Correlation analysis between body mass index and clinical characteristics of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 993-999.
[7] Yin-ji JIN,Lin SUN,Jin-xia ZHAO,Xiang-yuan LIU. Significance of IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 antibody in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 631-635.
[8] Wen-xin CAI,Shi-cheng LI,Yi-ming LIU,Ru-yu LIANG,Jing LI,Jian-ping GUO,Fan-lei HU,Xiao-lin SUN,Chun LI,Xu LIU,Hua YE,Li-zong DENG,Ru LI,Zhan-guo LI. A cross-sectional study on the clinical phenotypes of rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1068-1073.
[9] Fang CHENG,Shao-ying YANG,Xing-xing FANG,Xuan WANG,Fu-tao ZHAO. Role of the CCL28-CCR10 pathway in monocyte migration in rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1074-1078.
[10] Rui LIU,Jin-xia ZHAO,Liang YAN. Clinical characteristics of patients with rheumatoid arthritis complicated with venous thrombosis of lower extremities [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1079-1085.
[11] Jing-feng ZHANG,Yin-ji JIN,Hui WEI,Zhong-qiang YAO,Jin-xia ZHAO. Cross-sectional study on quality of life and disease activity of rheumatoid arthritis patients [J]. Journal of Peking University (Health Sciences), 2022, 54(6): 1086-1093.
[12] GAO Chao,CHEN Li-hong,WANG Li,YAO Hong,HUANG Xiao-wei,JIA Yu-bo,LIU Tian. Validation of the Pollard’s classification criteria (2010) for rheumatoid arthritis patients with fibromyalgia [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 278-282.
[13] LUO Liang,HUO Wen-gang,ZHANG Qin,LI Chun. Clinical characteristics and risk factors of rheumatoid arthritis with ulcerative keratitis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1032-1036.
[14] ZHONG Hua,XU Li-ling,BAI Ming-xin,SU Yin. Effect of chemokines CXCL9 and CXCL10 on bone erosion in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1026-1031.
[15] LOU Xue,LIAO Li,LI Xing-jun,WANG Nan,LIU Shuang,CUI Ruo-mei,XU Jian. Methylation status and expression of TWEAK gene promoter region in peripheral blood of patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1020-1025.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!